sutures newsletter

PRODUCED BY AND FOR MEMBERS OF THE DEPARTMENT OF SURGERY September 2012 Issue | Archived Issues

Physician news

Nicholas Nissen, MD, has been appointed as director of Hepatobiliary and Pancreatic Surgery at Cedars-Sinai.


Featured publication

The following article was published by members of the Department of Surgery:


Grant announcements

The Department of Surgery Research Division would like to congratulate the following grant recipients:


Mark your calendar


Grand rounds

Click here to view a schedule of all upcoming grand rounds.


Surgery scheduling

Click the "read more" for hours and contact information for surgery scheduling.

Share Your News

Know an interesting colleague we should profile? A story we should tell? Submit your ideas, meetings and events for consideration.

Click here to submit your news to Sutures

FDA alerts for Revatio, stomach acid drugs

Pharmacy focus

Revatio® not recommended for children

Revatio® (sildenafil) should not be prescribed to children (ages 1 through 17) for pulmonary arterial hypertension, according to an alert from the U.S. Food and Drug Administration.

The FDA's recommendation is based on a recent long-term clinical pediatric trial showing the following:

  • children taking a high dose of Revatio had a higher risk of death than children taking a low dose
  • the low doses of Revatio are not effective in improving exercise ability

Treatment of pulmonary arterial hypertension in children with this drug is an off-label use.

Revatio is a phosphodiesterase-5 inhibitor used to treat pulmonary arterial hypertension by relaxing the blood vessels in the lungs to reduce blood pressure and is approved to improve exercise ability and delay clinical worsening of PAH in adult patients (WHO Group I).

Click here to read the safety alert.

Clostridium difficile-associated diarrhea and stomach acid drugs

The use of stomach acid drugs known as proton pump inhibitors may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), according to the FDA. A diagnosis of CDAD should be considered for patients taking proton pump inhibitors who develop diarrhea that does not improve.

The FDA also is reviewing the risk of CDAD in users of histamine H2 receptor blockers. H2 receptor blockers are used to treat conditions such as gastroesophageal reflux disease (GERD), stomach and small intestine ulcers, and heartburn.

Proton pump inhibitors include:

  • AcipHex® (rabeprazole sodium)
  • Dexilant® (dexlansoprazole)
  • Nexium® (esomeprazole magnesium)
  • Omeprazole® (omeprazole) OTC
  • Prevacid® (lansoprazole) and OTC Prevacid 24hr
  • Prilosec® (omeprazole) and OTC
  • Protonix® (pantoprazole sodium)
  • Vimovo® (esomeprazole magnesium and naproxen)
  • Zegerid® (omeprazole and sodium bicarbonate) and OTC

Click here to read the safety alert.